Daniel V Araujo, MD

Oncologist (Cancer Specialist)

Additional languages:: Portuguese

(352) 733-0111 MyUFHealth

Research at a glance

Top areas of exploration

Neoplasms , 8 publications
Immune Checkpoint Inhibitors , 5 publications
Immunotherapy , 5 publications
Circulating Tumor DNA , 4 publications

Research activity

31 publications

652 citations

Why is this important?

Active clinical trials

Addition of Pembrolizumab to RT Compared to the Usual Chemo Tx during RT for bladder CA (PARRC)

This phase II trial compares the use of pembrolizumab and radiation therapy to chemotherapy with cisplatin, gemcitabine, 5-fluorouracil or mitomycin-C and radiation therapy for the treatment of non-muscle invasive bladder cancer. Immunotherapy with…

Investigator: Daniel V Araujo
Status: Accepting Candidates
Ages: 18 Years - N/A
Sexes: All

Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surger

This phase III trial compares the effect of adding tivozanib to standard therapy pembrolizumab versus pembrolizumab alone for the treatment of patients with high-risk renal cell carcinoma (RCC). Immunotherapy with monoclonal antibodies, such as…

Investigator: Daniel V Araujo
Status: Accepting Candidates
Ages: 18 Years - N/A
Sexes: All

My publications

31 publications

2025

Dabrafenib and trametinib vs anti-PD(L)1 for the adjuvant treatment of locally advanced BRAF-mutant melanoma: a systematic review and meta-analysis.

The oncologist

PubMed • Publisher's site

2024

Bespoke ctDNA for longitudinal detection of molecular residual disease in high-risk melanoma patients

ESMO Open

PubMed • Publisher's site

2024

Low-Dose Anti-PD(L)1 for the Treatment of Solid Malignancies.

JCO global oncology

PubMed • Publisher's site

2024

Advanced renal cell carcinoma management: the Latin American Cooperative Oncology Group (LACOG) and the Latin American Renal Cancer Group (LARCG) consensus update

Journal of Cancer Research and Clinical Oncology

PubMed • Publisher's site

2023

First-in-class Microbial Ecosystem Therapeutic 4 (MET4) in combination with immune checkpoint inhibitors in patients with advanced solid tumors (MET4-IO trial)

Annals of Oncology

Publisher's site

Research at a glance

Top areas of exploration

Research activity

Active clinical trials

My publications

Filter publications

Dabrafenib and trametinib vs anti-PD(L)1 for the adjuvant treatment of locally advanced BRAF-mutant melanoma: a systematic review and meta-analysis.

Bespoke ctDNA for longitudinal detection of molecular residual disease in high-risk melanoma patients

Low-Dose Anti-PD(L)1 for the Treatment of Solid Malignancies.

Advanced renal cell carcinoma management: the Latin American Cooperative Oncology Group (LACOG) and the Latin American Renal Cancer Group (LARCG) consensus update

First-in-class Microbial Ecosystem Therapeutic 4 (MET4) in combination with immune checkpoint inhibitors in patients with advanced solid tumors (MET4-IO trial)